Michigan Growth Capital Symposium Unveils Flagship Ventures' Noubar Afeyan as Keynote Speaker

Michigan Growth Capital Symposium Unveils Flagship Ventures' Noubar Afeyan as Keynote Speaker

April 24, 2012

Society for Biological Engineering Announces Inaugural Winners of Wang Award

Society for Biological Engineering Announces Inaugural Winners of Wang Award

April 17, 2012

NEW YORK – The Society for Biological Engineering (SBE) of the American Institute of Chemical Engineers (AIChE) has announced the inaugural winners of the D. I. C. Wang Award for Excellence in Biochemical Engineering. The inaugural recipients of the award, established in appreciation of Professor Daniel I.C. Wang of the Massachusetts Institute of Technology (MIT), are Noubar Afeyan of Flagship Ventures and James Swartz of Stanford University.

Shire Adds new Technology Platform and Phase 2 Product Candidate to its Regenerative Medicine Business

Shire Adds new Technology Platform and Phase 2 Product Candidate to its Regenerative Medicine Business

April 12, 2012
DUBLIN, April 12, 2012 /PRNewswire/ --

Tangent Medical Submits FDA 510(k) for NovaCath™ Secure IV Catheter System

Tangent Medical Submits FDA 510(k) for NovaCath™ Secure IV Catheter System

April 10, 2012
Innovative Closed Catheter System To Offer Advanced Catheter Stabilization On Every Single Start
BIND Therapeutics, Inc.

First Targeted Nanomedicine to Enter Human Clinical Studies is a Paradigm Shift in Anti-tumor Efficacy and Safety in Cancer Patients

First Targeted Nanomedicine to Enter Human Clinical Studies is a Paradigm Shift in Anti-tumor Efficacy and Safety in Cancer Patients

April 4, 2012

BOSTON, MA—A team of scientists, engineers and physicians from Brigham and Women’s Hospital (BWH), Dana-Farber Cancer Institute (DFCI), Harvard Medical School (HMS), Massachusetts Institute of Technology (MIT), BIND Biosciences, Translational Genomics Research Institute (TGen), Wayne State University Karmanos Cancer Institute, and Weill Cornell Medical College have found promising effects of a first-in-class targeted cancer drug called BIND-014 in treating solid tumors.

BIND Therapeutics, Inc.

Novel Prostate Nanomedicine Delivers High Drug Concentration Directlyand Safely to Tumors in Phase I Trials

Novel Prostate Nanomedicine Delivers High Drug Concentration Directlyand Safely to Tumors in Phase I Trials

April 4, 2012

Highly-Targeted Nanoparticles Act as “Trojan Horse” to Deliver Powerful Chemotherapy Agent Without Affecting Healthy Cells

Acceleron Pharma, Inc.

Acceleron’s ACE-041 Combined with a VEGF Inhibitor Shows Potent Activity in Preclinical Model of VEGF-Resistant Renal Cell Carcinoma

Acceleron’s ACE-041 Combined with a VEGF Inhibitor Shows Potent Activity in Preclinical Model of VEGF-Resistant Renal Cell Carcinoma

April 3, 2012

-- Enhanced Anti-Tumor Activity Achieved via Combination of Two Distinct Anti-Angiogenic Drugs presented at the AACR Annual Meeting 2012 --

BIND Therapeutics, Inc.

Bind Biosciences - Fierce's 5 Drug Delivery Companies to Watch

Bind Biosciences - Fierce's 5 Drug Delivery Companies to Watch

March 27, 2012

Company: Bind Biosciences
Headquarters: Cambridge, MA
Founded: 2006
Employees: 30

Core drug delivery technology: Bind's Accurins technology blends polymers with existing drugs to create an enhanced, controlled-release compound that hits a precise target with its payload. Bind's first drug, Bind-014, is a formulation of docetaxel, the active ingredient in Taxotere, a drug that treats breast, prostate, lung and other cancers.

Tetraphase Pharmaceuticals, Inc.

Tetraphase Presents Data at ECCMID from Growing Portfolio of Next-Generation Antibiotic Candidates

Tetraphase Presents Data at ECCMID from Growing Portfolio of Next-Generation Antibiotic Candidates

April 2, 2012
- Data Highlight Enhanced Potency and Favorable Pharmacokinetics of New Agents Against Pseudomonas and Gram-Negative Respiratory Pathogens -
Avedro, Inc.

ACOS and Avedro Announce Initiation of a Phase 3 Study On Accelerated Corneal Cross-Linking

ACOS and Avedro Announce Initiation of a Phase 3 Study On Accelerated Corneal Cross-Linking

April 3, 2012

ACOS (The American-European Congress of Ophthalmic Surgery) and Avedro, Inc. jointly announced today the initiation of a Phase 3, multi-center, randomized, controlled evaluation to study accelerated corneal collagen cross-linking in eyes with keratoconus or corneal ectasia after refractive surgery. ACOS is sponsoring the study, which will be conducted in 100 clinical centers across the United States.